Biotech Values

[DewDiligence]

Bayer expects Xarelto approval in China for AF/stroke prevention during 2013:

http://www.reuters.com/article/2012/02/09/healthcare-bayer-china-idUSL4E8D90Z920120209

Xarelto has already won approvals from the United States, European Union, Malaysia and Japan for use to prevent stroke in patients with atrial fibrillation, or an irregular heartbeat. Approvals from other countries are expected in coming months.

…One out of every five deaths in China is now due to stroke…

A remarkable figure; however, not all stroke deaths are related to attril fib, so the above overstates the addressable market for Xarelto to some degree.